Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, alongside updates on its pipeline of non-opioid pain and neuropathy treatments. The Alpharetta, Georgia-based company emphasized strong operational momentum driven by progress in its two lead candidates, Halneuron and SP16.
Halneuron, a non-opioid NaV 1.7 inhibitor, is currently in a Phase 2b trial for chemotherapy-induced neuropathic pain (CINP). The company has enrolled 164 patients, with top-line results anticipated in the fall of 2026. Halneuron has received fast track designation from the FDA for CINP, highlighting its potential to address a significant unmet need in pain management.
SP16, a low-density lipoprotein receptor related protein-1 (LRP1) agonist, received IND approval from the FDA and is set to begin enrollment in mid-2026 for a Phase 1b trial targeting chemotherapy-induced peripheral neuropathy and pain (CIPPN). The trial is fully funded by the National Cancer Institute and will be conducted at the University of Virginia. SP16 has shown preclinical potential to reduce inflammatory cytokines and repair damaged tissue, offering a novel approach to neuropathy treatment.
In January 2026, Dogwood completed a financing of up to $26.9 million, with gross proceeds of $12.5 million received to date, to support Halneuron through Phase 2b development. As of March 31, 2026, the company had cash and cash equivalents of $13.2 million, providing operational runway into the fourth quarter of 2026.
For the first quarter of 2026, research and development expenses were $2.7 million, up from $2.4 million in the same period in 2025, driven by increased drug development costs for Halneuron and higher personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to increased salaries and personnel costs. Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the first quarter of 2025. The prior year period included a $6.1 million loss on debt conversion with a related party.
Dogwood also executed a global development license for its legacy combination antiviral assets, though terms were not disclosed. The company's largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange.
For more information, visit www.dwtx.com.
